Request Trial
apatsara-shutterstock-com-1
Apatsara / Shutterstock.com
1 October 2015PharmaArty Rajendra

Warner-Lambert v Actavis: lessons from ‘the case of the year’

On September 10, 2015 Mr Justice Arnold gave his judgment in the Lyrica (pregabalin) case at the English High Court. UK legal commentators have described this dispute between Warner-Lambert (Pfizer) and Actavis and Mylan as ‘the case of the year’. The litigation has already spawned five previous judgments, mainly interim skirmishes between Warner-Lambert and Actavis, but also a related application against NHS England.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
Lilly mounts defence as generics circle Mounjaro and Zepbound
11 August 2026   A litigation campaign against generic drugmakers, including Sandoz, Hikma, and Amenal, raise the stakes in the fight over two of the world’s most lucrative weight loss and diabetes treatments.
Pharma
Reading Stief, Haedicke and Wünsche, with the memory of a decade fought in Germany
10 August 2026   Takanori Abe of Abe & Partners brings the perspective of a lawyer with first-hand experience in the German courtrooms to Pharmaceutical, Biological and Chemical Patents, a valuable resource on case law.
Pharma
Novo’s Dutch win sends ‘clear message’ to unapproved semaglutide sellers
6 August 2026   A Netherlands court ruling marks the latest win as Novo Nordisk ramps up efforts to protect semaglutide from unapproved products, copycats and an increasingly competitive market.


Editor's picks

Where Big Pharma is betting big in the M&A boom
Regulation & Industry
Where Big Pharma is betting big in the M&A boom
29 July 2026

Editor's picks

Regulation & Industry
Where Big Pharma is betting big in the M&A boom
29 July 2026
Regulation & Industry
Why is 2026 already a record year for M&A activity?
17 July 2026
Biotech
Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer
15 July 2026
Pharma
What’s at stake in Australia’s biggest pharma patent appeal in years?
1 July 2026
Biotech
Pfizer’s US Paxlovid patent fight turns on a single error
25 June 2026
Regulation & Industry
Novartis and Eli Lilly sign separate $1.9bn novel drug deals
25 June 2026

More features

Lilly mounts defence as generics circle Mounjaro and Zepbound
Reading Stief, Haedicke and Wünsche, with the memory of a decade fought in Germany
The UPC plugs another gap in its procedural rulebook
Novo’s Dutch win sends ‘clear message’ to unapproved semaglutide sellers
Fran Salisbury: ‘There’s nothing quite like finding the missing piece’
Patent litigator joins Baker Botts in London as UPC grows in significance
Exclusive: Winston Taylor’s UK head of IP on pitching $1.75bn firm’s ‘humble, but lethal’ practice
USPTO director steps into Sun Pharma’s PTAB-ITC clash